The type I interferons: Basic concepts and clinical relevance in immune-mediated inflammatory diseases

Gene

Volumn 576, Issue 1, 2016, Pages 14-21

  López de Padilla, Consuelo M ^a   Niewold, Timothy B ^a  

^a MAYO GRADUATE SCHOOL   (United States)

Author keywords

Autoimmune diseases; Idiopathic inflammatory myopathies; Interferon alpha; Interferon beta; Interferon signature; Multiple sclerosis; Rheumatoid arthritis; Systemic lupus erythematosus

Indexed keywords

ALPHA INTERFERON; INTERFERON; JANUS KINASE; STAT PROTEIN; TOLL LIKE RECEPTOR;

AUTOIMMUNITY; HUMAN; INFLAMMATORY DISEASE; MULTIGENE FAMILY; MULTIPLE SCLEROSIS; MYOSITIS; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; AUTOIMMUNE DISEASE; GENETICS; HISTORY; IMMUNOLOGY; INFLAMMATION; PATHOLOGY;

ANIMALS; AUTOIMMUNE DISEASES; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; INFLAMMATION; INTERFERON TYPE I; JANUS KINASES; STAT TRANSCRIPTION FACTORS;

EID: 84945939637     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2015.09.058     Document Type: Review

References (127)

1. Aaronson D.S., Horvath C.M. A road map for those who don't know JAK-STAT. Science 2002, 296:1653-1655.
2. Alexopoulou L., Holt A.C., Medzhitov R., Flavell R.A. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001, 413:732-738.
3. Arduini R.M., Strauch K.L., Runkel L.A., Carlson M.M., Hronowski X., Foley S.F., Young C.N., Cheng W., Hochman P.S., Baker D.P. Characterization of a soluble ternary complex formed between human interferon-beta-1a and its receptor chains. Protein Sci. 1999, 8:1867-1877.
4. Aringer M., Crow M.K. A bridge between interferon-alpha and tumor necrosis factor in lupus. J. Rheumatol. 2008, 35:1473-1476.
5. Aringer M., Graninger W.B., Steiner G., Smolen J.S. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum. 2004, 50:3161-3169.
6. Asarch A., Gottlieb A.B., Lee J., Masterpol K.S., Scheinman P.L., Stadecker M.J., Massarotti E.M., Bush M.L. Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonists. J. Am. Acad. Dermatol. 2009, 61:104-111.
7. Baccala R., Hoebe K., Kono D.H., Beutler B., Theofilopoulos A.N. TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat. Med. 2007, 13:543-551.
8. Bacher N., Raker V., Hofmann C., Graulich E., Schwenk M., Baumgrass R., Bopp T., Zechner U., Merten L., Becker C., Steinbrink K. Interferon-alpha suppresses cAMP to disarm human regulatory T cells. Cancer Res. 2013, 73:5647-5656.
9. Baechler E.C., Batliwalla F.M., Karypis G., Gaffney P.M., Ortmann W.A., Espe K.J., Shark K.B., Grande W.J., Hughes K.M., Kapur V., Gregersen P.K., Behrens T.W. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:2610-2615.
10. Baechler E.C., Bauer J.W., Slattery C.A., Ortmann W.A., Espe K.J., Novitzke J., Ytterberg S.R., Gregersen P.K., Behrens T.W., Reed A.M. An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol. Med. 2007, 13:59-68.
11. Balboni I., Niewold T.B., Morgan G., Limb C., Eloranta M.L., Ronnblom L., Utz P.J., Pachman L.M. Interferon-alpha induction and detection of anti-ro, anti-la, anti-sm, and anti-rnp autoantibodies by autoantigen microarray analysis in juvenile dermatomyositis. Arthritis Rheum. 2013, 65:2424-2429.
12. Cacopardo B., Benanti F., Pinzone M.R., Nunnari G. Rheumatoid arthritis following PEG-interferon-alfa-2a plus ribavirin treatment for chronic hepatitis C: a case report and review of the literature. BMC Res. Notes 2013, 6:437.
13. Cappelletti C., Baggi F., Zolezzi F., Biancolini D., Beretta O., Severa M., Coccia E.M., Confalonieri P., Morandi L., Mora M., Mantegazza R., Bernasconi P. Type I interferon and Toll-like receptor expression characterizes inflammatory myopathies. Neurology 2011, 76:2079-2088.
14. Chen J.M., Cooper D.N., Chuzhanova N., Ferec C., Patrinos G.P. Gene conversion: mechanisms, evolution and human disease. Nat. Rev. Genet. 2007, 8:762-775.
15. Cherian T.S., Kariuki S.N., Franek B.S., Buyon J.P., Clancy R.M., Niewold T.B. Brief report: IRF5 systemic lupus erythematosus risk haplotype is associated with asymptomatic serologic autoimmunity and progression to clinical autoimmunity in mothers of children with neonatal lupus. Arthritis Rheum. 2012, 64:3383-3387.
16. Cohen B., Novick D., Barak S., Rubinstein M. Ligand-induced association of the type I interferon receptor components. Mol. Cell. Biol. 1995, 15:4208-4214.
17. Comabella M., Lunemann J.D., Rio J., Sanchez A., Lopez C., Julia E., Fernandez M., Nonell L., Camina-Tato M., Deisenhammer F., Caballero E., Tortola M.T., Prinz M., Montalban X., Martin R. A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain 2009, 132:3353-3365.
18. Crow M.K., Kirou K.A., Wohlgemuth J. Microarray analysis of interferon-regulated genes in SLE. Autoimmunity 2003, 36:481-490.
19. Dastmalchi M., Grundtman C., Alexanderson H., Mavragani C.P., Einarsdottir H., Helmers S.B., Elvin K., Crow M.K., Nennesmo I., Lundberg I.E. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann. Rheum. Dis. 2008, 67:1670-1677.
20. David M. Signal transduction by type I interferons. Biotechniques 2002, 58-65. (Suppl).
21. Lopez de Padilla C.M., Vallejo A.A.N., McNallan K.T., Vehe R., Smith S.A., Dietz A.A.B., Vuk-Pavlovic S., Reed A.A.M. Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis. Arthritis Rheum. 2007, 56:1658-1668.
22. Denadai R., Teixeira F.V., Steinwurz F., Romiti R., Saad-Hossne R. Induction or exacerbation of psoriatic lesions during anti-TNF-alpha therapy for inflammatory bowel disease: a systematic literature review based on 222 cases. J. Crohn's Colitis 2013, 7:517-524.
23. Diaz M.O., Pomykala H.M., Bohlander S.K., Maltepe E., Malik K., Brownstein B., Olopade O.I. Structure of the human type-I interferon gene cluster determined from a YAC clone contig. Genomics 1994, 22:540-552.
24. Diaz M.O., Bohlander S., Allen G. Nomenclature of the human interferon genes. J. Interferon Cytokine Res. 1996, 16:179-180.
25. Ding C., Cai Y., Marroquin J., Ildstad S.T., Yan J. Plasmacytoid dendritic cells regulate autoreactive B cell activation via soluble factors and in a cell-to-cell contact manner. J. Immunol. 2009, 183:7140-7149.
26. Dipaola M., Smith T., Ferencz-Biro K., Liao M.J., Testa D. Interferon-alpha 2 produced by normal human leukocytes is predominantly interferon-alpha 2b. J. Interf. Res. 1994, 14:325-332.
27. Eloranta M.L., Barbasso Helmers S., Ulfgren A.K., Ronnblom L., Alm G.V., Lundberg I.E. A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies. Arthritis Rheum. 2007, 56:3112-3124.
28. Eriksen K.W., Lovato P., Skov L., Krejsgaard T., Kaltoft K., Geisler C., Odum N. Increased sensitivity to interferon-alpha in psoriatic T cells. J. Invest. Dermatol. 2005, 125:936-944.
29. Feldmann M., Maini R.N. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?. Annu. Rev. Immunol. 2001, 19:163-196.
30. Feng X., Petraglia A.L., Chen M., Byskosh P.V., Boos M.D., Reder A.T. Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1. J. Neuroimmunol. 2002, 129:205-215.
31. Feng X., Wu H., Grossman J.M., Hanvivadhanakul P., FitzGerald J.D., Park G.S., Dong X., Chen W., Kim M.H., Weng H.H., Furst D.E., Gorn A., McMahon M., Taylor M., Brahn E., Hahn B.H., Tsao B.P. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum. 2006, 54:2951-2962.
32. Feng D., Stone R.C., Eloranta M.L., Sangster-Guity N., Nordmark G., Sigurdsson S., Wang C., Alm G., Syvanen A.C., Ronnblom L., Barnes B.J. Genetic variants and disease-associated factors contribute to enhanced interferon regulatory factor 5 expression in blood cells of patients with systemic lupus erythematosus. Arthritis Rheum. 2010, 62:562-573.
33. Feng X., Reder N.P., Yanamandala M., Hill A., Franek B.S., Niewold T.B., Reder A.T., Javed A. Type I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosis. J. Neurol. Sci. 2012, 313:48-53.
34. Fiorentino D.F. The Yin and Yang of TNF-alpha inhibition. Arch. Dermatol. 2007, 143:233-236.
35. Flendrie M., Vissers W.H., Creemers M.C., de Jong E.M., van de Kerkhof P.C., van Riel P.L. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res. Ther. 2005, 7:R666-R676.
36. Foster G.R., Rodrigues O., Ghouze F., Schulte-Frohlinde E., Testa D., Liao M.J., Stark G.R., Leadbeater L., Thomas H.C. Different relative activities of human cell-derived interferon-alpha subtypes: IFN-alpha 8 has very high antiviral potency. J. Interferon Cytokine Res. 1996, 16:1027-1033.
37. Frohman E.M., Racke M.K., Raine C.S. Multiple sclerosis-the plaque and its pathogenesis. N. Engl. J. Med. 2006, 354:942-955.
38. Graham R.R., Kozyrev S.V., Baechler E.C., Reddy M.V., Plenge R.M., Bauer J.W., Ortmann W.A., Koeuth T., Gonzalez Escribano M.F., Pons-Estel B., Petri M., Daly M., Gregersen P.K., Martin J., Altshuler D., Behrens T.W., Alarcon-Riquelme M.E. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat. Genet. 2006, 38:550-555.
39. Greenberg S.A., Pinkus J.L., Pinkus G.S., Burleson T., Sanoudou D., Tawil R., Barohn R.J., Saperstein D.S., Briemberg H.R., Ericsson M., Park P., Amato A.A. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann. Neurol. 2005, 57:664-678.
40. Harle P., Cull V., Guo L., Papin J., Lawson C., Carr D.J. Transient transfection of mouse fibroblasts with type I interferon transgenes provides various degrees of protection against herpes simplex virus infection. Antivir. Res. 2002, 56:39-49.
41. Hertzog P.J., Wright A., Harris G., Linnane A.W., Mackay I.R. Intermittent interferonemia and interferon responses in multiple sclerosis. Clin. Immunol. Immunopathol. 1991, 58:18-32.
42. Hibbert L., Foster G.R. Human type I interferons differ greatly in their effects on the proliferation of primary B cells. J. Interferon Cytokine Res. 1999, 19:309-318.
43. Higgs B.W., Liu Z., White B., Zhu W., White W.I., Morehouse C., Brohawn P., Kiener P.A., Richman L., Fiorentino D., Greenberg S.A., Jallal B., Yao Y. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann. Rheum. Dis. 2011, 70:2029-2036.
44. Hilkens C.M., Schlaak J.F., Kerr I.M. Differential responses to IFN-alpha subtypes in human T cells and dendritic cells. J. Immunol. 2003, 171:5255-5263.
45. Hillyer P., Mane V.P., Schramm L.M., Puig M., Verthelyi D., Chen A., Zhao Z., Navarro M.B., Kirschman K.D., Bykadi S., Jubin R.G., Rabin R.L. Expression profiles of human interferon-alpha and interferon-lambda subtypes are ligand- and cell-dependent. Immunol. Cell Biol. 2012, 90:774-783.
46. Ho H.H., Ivashkiv L.B. Role of STAT3 in type I interferon responses. Negative regulation of STAT1-dependent inflammatory gene activation. J. Biol. Chem. 2006, 281:14111-14118.
47. Honda K., Taniguchi T. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat. Rev. Immunol. 2006, 6:644-658.
48. Honda K., Taniguchi T. Toll-like receptor signaling and IRF transcription factors. IUBMB life 2006, 58:290-295.
49. Honda K., Yanai H., Negishi H., Asagiri M., Sato M., Mizutani T., Shimada N., Ohba Y., Takaoka A., Yoshida N., Taniguchi T. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 2005, 434:772-777.
50. Hughes A.L. The evolution of the type I interferon gene family in mammals. J. Mol. Evol. 1995, 41:539-548.
51. Hundeshagen A., Hecker M., Paap B.K., Angerstein C., Kandulski O., Fatum C., Hartmann C., Koczan D., Thiesen H.J., Zettl U.K. Elevated type I interferon-like activity in a subset of multiple sclerosis patients: molecular basis and clinical relevance. J. Neuroinflammation 2012, 9:140.
52. Ionescu C., Micu L., Constantinescu I., Hortopan M., Ursaciuc C., Voiculescu M. Prolonged treatment with interferon alpha and peginterferon induces rheumatoid arthritis syndrome and erythema nodosum. J. Gastrointestin. Liver Dis. 2008, 17:211-212.
53. Isaacs A., Lindenmann J. Virus interference. I. The interferon. Proc. R. Soc. Lond. B Biol. Sci. 1957, 147:258-267.
54. Isaacs A., Lindenmann J., Valentine R.C. Virus interference. II. Some properties of interferon. Proc. R. Soc. Lond. B Biol. Sci. 1957, 147:268-273.
55. Jacobs L.D., Cookfair D.L., Rudick R.A., Herndon R.M., Richert J.R., Salazar A.M., Fischer J.S., Goodkin D.E., Granger C.V., Simon J.H., Alam J.J., Bartoszak D.M., Bourdette D.N., Braiman J., Brownscheidle C.M., Coats M.E., Cohan S.L., Dougherty D.S., Kinkel R.P., Mass M.K., Munschauer F.E., Priore R.L., Pullicino P.M., Scherokman B.J., Whitham R.H., et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann. Neurol. 1996, 39:285-294.
56. Jensen M.A., Niewold T.B. Interferon regulatory factors: critical mediators of human lupus. Transl. Res. 2015, 165:283-295.
57. Kariuki S.N., Kirou K.A., MacDermott E.J., Barillas-Arias L., Crow M.K., Niewold T.B. Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo. J. Immunol. 2009, 182:34-38.
58. Karpusas M., Nolte M., Benton C.B., Meier W., Lipscomb W.N., Goelz S. The crystal structure of human interferon beta at 2.2-A resolution. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:11813-11818.
59. Kawai T., Akira S. TLR signaling. Cell Death Differ. 2006, 13:816-825.
60. Kawasaki A., Kyogoku C., Ohashi J., Miyashita R., Hikami K., Kusaoi M., Tokunaga K., Takasaki Y., Hashimoto H., Behrens T.W., Tsuchiya N. Association of IRF5 polymorphisms with systemic lupus erythematosus in a Japanese population: support for a crucial role of intron 1 polymorphisms. Arthritis Rheum. 2008, 58:826-834.
61. Ko K., Koldobskaya Y., Rosenzweig E., Niewold T.B. Activation of the interferon pathway is dependent upon autoantibodies in African-American SLE patients, but not in European-American SLE patients. Front. Immunol. 2013, 4:309.
62. Le Bon A., Durand V., Kamphuis E., Thompson C., Bulfone-Paus S., Rossmann C., Kalinke U., Tough D.F. Direct stimulation of T cells by type I IFN enhances the CD8+ T cell response during cross-priming. J. Immunol. 2006, 176:4682-4689.
63. Lengyel P. Biochemistry of interferons and their actions. Annu. Rev. Biochem. 1982, 51:251-282.
64. Lovgren T., Eloranta M.L., Bave U., Alm G.V., Ronnblom L. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum. 2004, 50:1861-1872.
65. Lovgren T., Eloranta M.L., Kastner B., Wahren-Herlenius M., Alm G.V., Ronnblom L. Induction of interferon-alpha by immune complexes or liposomes containing systemic lupus erythematosus autoantigen- and Sjogren's syndrome autoantigen-associated RNA. Arthritis Rheum. 2006, 54:1917-1927.
66. Matas E., Bau L., Martinez-Iniesta M., Romero-Pinel L., Mane M.A., Cobo-Calvo A., Martinez-Yelamos S. Baseline MxA mRNA expression predicts interferon beta response in multiple sclerosis patients. PLoS One 2014, 9.
67. Mavragani C.P., Niewold T.B., Moutsopoulos N.M., Pillemer S.R., Wahl S.M., Crow M.K. Augmented interferon-alpha pathway activation in patients with Sjogren's syndrome treated with etanercept. Arthritis Rheum. 2007, 56:3995-4004.
68. Mavragani C.P., La D.T., Stohl W., Crow M.K. Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-beta/alpha ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohort. Arthritis Rheum. 2010, 62:392-401.
69. Means T.K., Latz E., Hayashi F., Murali M.R., Golenbock D.T., Luster A.D. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J. Clin. Invest. 2005, 115:407-417.
70. Mitsui Y., Senda T. Elucidation of the basic three-dimensional structure of type I interferons and its functional and evolutionary implications. J. Interferon Cytokine Res. 1997, 17:319-326.
71. Mowen K., David M. Role of the STAT1-SH2 domain and STAT2 in the activation and nuclear translocation of STAT1. J. Biol. Chem. 1998, 273:30073-30076.
72. Nagaraju K., Casciola-Rosen L., Lundberg I., Rawat R., Cutting S., Thapliyal R., Chang J., Dwivedi S., Mitsak M., Chen Y.W., Plotz P., Rosen A., Hoffman E., Raben N. Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. Arthritis Rheum. 2005, 52:1824-1835.
73. Niewold T.B. Interferon alpha-induced lupus: proof of principle. J. Clin. Rheumatol. 2008, 14:131-132.
74. Niewold T.B., Adler J.E., Glenn S.B., Lehman T.J., Harley J.B., Crow M.K. Age- and sex-related patterns of serum interferon-alpha activity in lupus families. Arthritis Rheum. 2008, 58:2113-2119.
75. Niewold T.B., Kelly J.A., Flesch M.H., Espinoza L.R., Harley J.B., Crow M.K. Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients. Arthritis Rheum. 2008, 58:2481-2487.
76. Niewold T.B., Rivera T.L., Buyon J.P., Crow M.K. Serum type I interferon activity is dependent on maternal diagnosis in anti-SSA/Ro-positive mothers of children with neonatal lupus. Arthritis Rheum. 2008, 58:541-546.
77. Niewold T.B., Kariuki S.N., Morgan G.A., Shrestha S., Pachman L.M. Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy. Arthritis Rheum. 2009, 60:1815-1824.
78. Niewold T.B., Kariuki S.N., Morgan G.A., Shrestha S., Pachman L.M. Gene-gene-sex interaction in cytokine gene polymorphisms revealed by serum interferon alpha phenotype in juvenile dermatomyositis. J. Pediatr. 2010, 157:653-657.
79. Niewold T.B., Wu S.C., Smith M., Morgan G.A., Pachman L.M. Familial aggregation of autoimmune disease in juvenile dermatomyositis. Pediatrics 2011, 127:e1239-e1246.
80. Niewold T.B., Kelly J.A., Kariuki S.N., Franek B.S., Kumar A.A., Kaufman K.M., Thomas K., Walker D., Kamp S., Frost J.M., Wong A.K., Merrill J.T., Alarcon-Riquelme M.E., Tikly M., Ramsey-Goldman R., Reveille J.D., Petri M.A., Edberg J.C., Kimberly R.P., Alarcon G.S., Kamen D.L., Gilkeson G.S., Vyse T.J., James J.A., Gaffney P.M., Moser K.L., Crow M.K., Harley J.B. IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosus. Ann. Rheum. Dis. 2012, 71:463-468.
81. Noseworthy J.H., Lucchinetti C., Rodriguez M., Weinshenker B.G. Multiple sclerosis. N. Engl. J. Med. 2000, 343:938-952.
82. Olsen N., Sokka T., Seehorn C.L., Kraft B., Maas K., Moore J., Aune T.M. A gene expression signature for recent onset rheumatoid arthritis in peripheral blood mononuclear cells. Ann. Rheum. Dis. 2004, 63:1387-1392.
83. Osterlund P.I., Pietila T.E., Veckman V., Kotenko S.V., Julkunen I. IFN regulatory factor family members differentially regulate the expression of type III IFN (IFN-lambda) genes. J. Immunol. 2007, 179:3434-3442.
84. Palucka A.K., Blanck J.P., Bennett L., Pascual V., Banchereau J. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:3372-3377.
85. Panitch H.S., Hirsch R.L., Haley A.S., Johnson K.P. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1987, 1:893-895.
86. Passos de Souza E., Evangelista Segundo P.T., Jose F.F., Lemaire D., Santiago M. Rheumatoid arthritis induced by alpha-interferon therapy. Clin. Rheumatol. 2001, 20:297-299.
87. Pestka S., Langer J.A., Zoon K.C., Samuel C.E. Interferons and their actions. Annu. Rev. Biochem. 1987, 56:727-777.
88. Pestka S., Krause C.D., Walter M.R. Interferons, interferon-like cytokines, and their receptors. Immunol. Rev. 2004, 202:8-32.
89. Popescu B.F., Pirko I., Lucchinetti C.F. Pathology of multiple sclerosis: where do we stand?. Continuum 2013, 19:901-921.
90. Reder A.T., Feng X. Aberrant type I interferon regulation in autoimmunity: opposite directions in MS and SLE, shaped by evolution and body ecology. Front. Immunol. 2013, 4:281.
91. Rekvig O.P., Nossent J.C. Anti-double-stranded DNA antibodies, nucleosomes, and systemic lupus erythematosus: a time for new paradigms?. Arthritis Rheum. 2003, 48:300-312.
92. Remmers E.F., Plenge R.M., Lee A.T., Graham R.R., Hom G., Behrens T.W., de Bakker P.I., Le J.M., Lee H.S., Batliwalla F., Li W., Masters S.L., Booty M.G., Carulli J.P., Padyukov L., Alfredsson L., Klareskog L., Chen W.V., Amos C.I., Criswell L.A., Seldin M.F., Kastner D.L., Gregersen P.K. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N. Engl. J. Med. 2007, 357:977-986.
93. Robinson T., Kariuki S.N., Franek B.S., Kumabe M., Kumar A.A., Badaracco M., Mikolaitis R.A., Guerrero G., Utset T.O., Drevlow B.E., Zaacks L.S., Grober J.S., Cohen L.M., Kirou K.A., Crow M.K., Jolly M., Niewold T.B. Autoimmune disease risk variant of IFIH1 is associated with increased sensitivity to IFN-alpha and serologic autoimmunity in lupus patients. J. Immunol. 2011, 187:1298-1303.
94. Ronnblom L., Eloranta M.L., Alm G.V. Role of natural interferon-alpha producing cells (plasmacytoid dendritic cells) in autoimmunity. Autoimmunity 2003, 36:463-472.
95. Salloum R., Niewold T.B. Interferon regulatory factors in human lupus pathogenesis. Transl. Res. 2011, 157:326-331.
96. Salloum R., Franek B.S., Kariuki S.N., Rhee L., Mikolaitis R.A., Jolly M., Utset T.O., Niewold T.B. Genetic variation at the IRF7/PHRF1 locus is associated with autoantibody profile and serum interferon-alpha activity in lupus patients. Arthritis Rheum. 2010, 62:553-561.
97. Sato M., Suemori H., Hata N., Asagiri M., Ogasawara K., Nakao K., Nakaya T., Katsuki M., Noguchi S., Tanaka N., Taniguchi T. Distinct and essential roles of transcription factors IRF-3 and IRF-7 in response to viruses for IFN-alpha/beta gene induction. Immunity 2000, 13:539-548.
98. Sekiguchi N., Kawauchi S., Furuya T., Inaba N., Matsuda K., Ando S., Ogasawara M., Aburatani H., Kameda H., Amano K., Abe T., Ito S., Takeuchi T. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab. Rheumatology 2008, 47:780-788.
99. Sfikakis P.P., Iliopoulos A., Elezoglou A., Kittas C., Stratigos A. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum. 2005, 52:2513-2518.
100. Shows T.B., Sakaguchi A.Y., Naylor S.L., Goedell D.V., Lawn R.M. Clustering of leukocyte and fibroblast interferon genes of human chromosome 9. Science 1982, 218:373-374.
101. Shrestha S., Wershil B., Sarwark J.F., Niewold T.B., Philipp T., Pachman L.M. Lesional and nonlesional skin from patients with untreated juvenile dermatomyositis displays increased numbers of mast cells and mature plasmacytoid dendritic cells. Arthritis Rheum. 2010, 62:2813-2822.
102. Sigurdsson S., Nordmark G., Goring H.H., Lindroos K., Wiman A.C., Sturfelt G., Jonsen A., Rantapaa-Dahlqvist S., Moller B., Kere J., Koskenmies S., Widen E., Eloranta M.L., Julkunen H., Kristjansdottir H., Steinsson K., Alm G., Ronnblom L., Syvanen A.C. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am. J. Hum. Genet. 2005, 76:528-537.
103. Sigurdsson S., Nordmark G., Garnier S., Grundberg E., Kwan T., Nilsson O., Eloranta M.L., Gunnarsson I., Svenungsson E., Sturfelt G., Bengtsson A.A., Jonsen A., Truedsson L., Rantapaa-Dahlqvist S., Eriksson C., Alm G., Goring H.H., Pastinen T., Syvanen A.C., Ronnblom L. A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5. Hum. Mol. Genet. 2008, 17:2868-2876.
104. Smiljanovic B., Grun J.R., Biesen R., Schulte-Wrede U., Baumgrass R., Stuhlmuller B., Maslinski W., Hiepe F., Burmester G.R., Radbruch A., Haupl T., Grutzkau A. The multifaceted balance of TNF-alpha and type I/II interferon responses in SLE and RA: how monocytes manage the impact of cytokines. J. Mol. Med. 2012, 90:1295-1309.
105. Sokumbi O., Wetter D.A., Makol A., Warrington K.J. Vasculitis associated with tumor necrosis factor-alpha inhibitors. Mayo Clin. Proc. 2012, 87:739-745.
106. Song G., Hsu C.H., Riemer C., Zhang Y., Kim H.L., Hoffmann F., Zhang L., Hardison R.C., Green E.D., Miller W. Conversion events in gene clusters. BMC Evol. Biol. 2011, 11:226.
107. Takeuchi O., Akira S. Pattern recognition receptors and inflammation. Cell 2010, 140:805-820.
108. Tezak Z., Hoffman E.P., Lutz J.L., Fedczyna T.O., Stephan D., Bremer E.G., Krasnoselska-Riz I., Kumar A., Pachman L.M. Gene expression profiling in DQA1 * 0501+ children with untreated dermatomyositis: a novel model of pathogenesis. J. Immunol. 2002, 168:4154-4163.
109. Thomas C., Moraga I., Levin D., Krutzik P.O., Podoplelova Y., Trejo A., Lee C., Yarden G., Vleck S.E., Glenn J.S., Nolan G.P., Piehler J., Schreiber G., Garcia K.C. Structural linkage between ligand discrimination and receptor activation by type I interferons. Cell 2011, 146:621-632.
110. Thurlings R.M., Boumans M., Tekstra J., van Roon J.A., Vos K., van Westing D.M., van Baarsen L.G., Bos C., Kirou K.A., Gerlag D.M., Crow M.K., Bijlsma J.W., Verweij C.L., Tak P.P. Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients. Arthritis Rheum. 2010, 62:3607-3614.
111. Tournadre A., Lenief V., Miossec P. Expression of Toll-like receptor 3 and Toll-like receptor 7 in muscle is characteristic of inflammatory myopathy and is differentially regulated by Th1 and Th17 cytokines. Arthritis Rheum. 2010, 62:2144-2151.
112. Tournadre A., Lenief V., Eljaafari A., Miossec P. Immature muscle precursors are a source of interferon-beta in myositis: role of Toll-like receptor 3 activation and contribution to HLA class I up-regulation. Arthritis Rheum. 2012, 64:533-541.
113. Tyler D.R., Persky M.E., Matthews L.A., Chan S., Farrar J.D. Pre-assembly of STAT4 with the human IFN-alpha/beta receptor-2 subunit is mediated by the STAT4 N-domain. Mol. Immunol. 2007, 44:1864-1872.
114. Uze G., Schreiber G., Piehler J., Pellegrini S. The receptor of the type I interferon family. Curr. Top. Microbiol. Immunol. 2007, 316:71-95.
115. van der Pouw Kraan T.C., Wijbrandts C.A., van Baarsen L.G., Voskuyl A.E., Rustenburg F., Baggen J.M., Ibrahim S.M., Fero M., Dijkmans B.A., Tak P.P., Verweij C.L. Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann. Rheum. Dis. 2007, 66:1008-1014.
116. van Holten J., Smeets T.J., Blankert P., Tak P.P. Expression of interferon beta in synovial tissue from patients with rheumatoid arthritis: comparison with patients with osteoarthritis and reactive arthritis. Ann. Rheum. Dis. 2005, 64:1780-1782.
117. Viscomi G.C. Structure-activity of type I interferons. Biotherapy 1997, 10:59-86.
118. Vitadello M., Doria A., Tarricone E., Ghirardello A., Gorza L. Myofiber stress-response in myositis: parallel investigations on patients and experimental animal models of muscle regeneration and systemic inflammation. Arthritis Res. Ther. 2010, 12:R52.
119. Wallace D.J., Petri M., Olsen N., Kirou K.A., Dennis G., Yao Y., Jallal B., Coyle A.J., Zeng L., White B. MEDI-545, an anti-interferon alpha monoclonal antibody, shows evidence of clinical activity in systemic lupus erythematosus. Arthritis Rheum. 2007, 56:S526-S527.
120. Weckerle C.E., Mangale D., Franek B.S., Kelly J.A., Kumabe M., James J.A., Moser K.L., Harley J.B., Niewold T.B. Large-scale analysis of tumor necrosis factor alpha levels in systemic lupus erythematosus. Arthritis Rheum. 2012, 64:2947-2952.
121. Williams E.L., Gadola S., Edwards C.J. Anti-TNF-induced lupus. Rheumatology 2009, 48:716-720.
122. Woelk C.H., Frost S.D., Richman D.D., Higley P.E., Kosakovsky Pond S.L. Evolution of the interferon alpha gene family in eutherian mammals. Gene 2007, 397:38-50.
123. Yan B., Ye S., Chen G., Kuang M., Shen N., Chen S. Dysfunctional CD4+,CD25+ regulatory T cells in untreated active systemic lupus erythematosus secondary to interferon-alpha-producing antigen-presenting cells. Arthritis Rheum. 2008, 58:801-812.
124. Yanai Y., Sanou O., Kayano T., Ariyasu H., Yamamoto K., Yamauchi H., Ikegami H., Kurimoto M. Analysis of the antiviral activities of natural IFN-alpha preparations and their subtype compositions. J. Interferon Cytokine Res. 2001, 21:835-841.
125. Yao Y., Richman L., Higgs B.W., Morehouse C.A., de los Reyes M., Brohawn P., Zhang J., White B., Coyle A.J., Kiener P.A., Jallal B. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum. 2009, 60:1785-1796.
126. Ytterberg S.R., Schnitzer T.J. Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum. 1982, 25:401-406.
127. Zhou X., Dimachkie M.M., Xiong M., Tan F.K., Arnett F.C. cDNA microarrays reveal distinct gene expression clusters in idiopathic inflammatory myopathies. Med. Sci. Monit. 2004, 10:BR191-BR197.